Brian R Rood
Affiliation: Children's National Medical Center
- Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approachesBrian R Rood
Division of Hematology Oncology, Center for Cancer and Immunology Research, Children s National Medical Center, Washington, DC 20010, USA
J Neurooncol 75:267-72. 2005....
- Intercellular heterogeneity of expression of the MGMT DNA repair gene in pediatric medulloblastomaBrian R Rood
Children s Research Institute, Children s National Medical Center, Washington, DC 20010, USA
Neuro Oncol 6:200-7. 2004..Further, these findings support the use of pharmacological MGMT depletion as a rational approach for intensification of alkylator chemotherapy in the treatment of medulloblastoma...
- Current treatment of medulloblastoma: recent advances and future challengesBrian R Rood
Division of Hematology Oncology, Center for Cancer Research, Children s National Medical Center, Washington, DC 20010, USA
Semin Oncol 31:666-75. 2004..Treatment for this disease has evolved a great deal over the preceding decades, but a great deal of work remains to be done to effect reliable cures while reducing long-term sequelae of therapy...
- The use of gene expression analysis to gain insights into signaling mechanisms of metastatic medulloblastomaArun Chopra
Department of Pediatrics, Children s National Medical Center, Washington, DC 20010, USA
Pediatr Neurosurg 39:68-74. 2003..We conclude that these genes may interact to promote prometastatic signaling in medulloblastoma...
- Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomasEugene I Hwang
Division of Oncology, Center for Cancer and Blood Disorders, Children s National Medical Center, Washington, District of Columbia, USA
Pediatr Blood Cancer 60:776-82. 2013..Bevacizumab-based therapy has demonstrated encouraging responses; however, longer-term toxicity, response durability and alternative dosing regimens have not been evaluated...
- A novel role of HLA class I in the pathology of medulloblastomaCourtney Smith
Center for Cancer and Immunology Research, Children s Research Institute, Children s National Medical Center, Washington, DC, USA
J Transl Med 7:59. 2009..However, in some cancer types MHC class I expression is associated with an unfavorable outcome. We explored the basis of MHC class I association with unfavorable prognostic marker expression in the case of medulloblastoma...
- Hypermethylation of HIC-1 and 17p allelic loss in medulloblastomaBrian R Rood
Department of Pediatric Hematology Oncology, Children s Research Institute, Children s National Medical Center, Washington, DC 20010, USA
Cancer Res 62:3794-7. 2002..014). The results of our study show that methylation of the CpG island that contains the HIC-1 gene is common in medulloblastoma and, together with LOH of 17p, may be a critical event in the formation and aggressiveness of this tumor...
- Medulloblastoma: present concepts of stratification into risk groupsRoger J Packer
Department of Neurology, Center for Neuroscience and Behavioral Medicine, Children s National Medical Center, Washington, DC 20010, USA
Pediatr Neurosurg 39:60-7. 2003..Biologic markers, especially molecular genetic findings, have not yet been incorporated into risk classifications, but will likely add to the understanding of medulloblastoma and may significantly alter concepts of staging and treatment...
- Durable response of intracranial cellular hemangioma to bevacizumab and temozolomideKee Kiat Yeo
Department of Pediatrics, Children s National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
J Neurosurg Pediatr 11:682-6. 2013..This is the first report of the successful use of chemotherapy to treat an intracranial hemangioma, a rare condition with limited therapeutic options...
- Advances in the proteomic investigation of the cell secretomeKristy J Brown
Children s National Medical Center, Center for Genetic Medicine Research, 111 Michigan Avenue NW, Washington, DC 20010, USA
Expert Rev Proteomics 9:337-45. 2012..In this review, some of the most recent advances in secretome studies and the fields that have benefited the most from this evolving technology are highlighted...
- Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium studyMeena U Rajagopal
Center for Genetic Medicine, Children s National Medical Center, Washington, DC, USA
Proteomics 11:935-43. 2011..In addition, our results demonstrate the feasibility of performing proteomic studies on CSF samples collected from patients at multiple institutions within the consortium setting...
- Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumorsTobey J Macdonald
Departments of Hematology Oncology, Children s Hospital National Medical Center, Washington, DC 20010, USA
Oncologist 8:174-86. 2003..In this review, recent advances in the diagnosis, molecular genetics, and treatment of the most common pediatric embryonal CNS tumors are discussed...
- Handheld optical coherence tomography during sedation in young children with optic pathway gliomasRobert A Avery
The Gilbert Family Neurofibromatosis Institute, Children s National Medical Center, Washington, DC2Department of Neurology, Children s National Medical Center, Washington, DC3Department of Ophthalmology, Children s National Medical Center, Washington, DC7
JAMA Ophthalmol 132:265-71. 2014..Optical coherence tomography (OCT) measures of retinal nerve fiber layer (RNFL) thickness have been proposed as a surrogate marker of vision but this technique is also limited by patient cooperation...
- Preclinical magnetic resonance imaging and systems biology in cancer research: current applications and challengesChris Albanese
Lombardi Comprehensive Cancer Center and Department of Oncology, Georgetown University Medical Center, Washington, District of Columbia 20057, USA
Am J Pathol 182:312-8. 2013..Finally, we provide new data from an ongoing preclinical drug study demonstrating how multiscale modeling can lead to a more comprehensive understanding of cancer biology and therapy...
- Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluidAmanda M Saratsis
Department of Neurosurgery, Georgetown University Hospital, Research Center for Genetic Medicine, Children s National Medical Center NW, Washington, DC 20010, USA
Neuro Oncol 14:547-60. 2012..Detection of secreted CypA and DDAH1 in serum and urine has potential clinical application, with implications for assessing treatment response and detecting tumor recurrence in patients with DIPG...
- Isolated extracranial recurrence of anaplastic ependymomaMwe Mwe Chao
Children s National Medical Center, Division of Pediatric Oncology, Washington, District of Columbia 20010, USA
Pediatr Blood Cancer 56:317-8. 2011..The location of tumor recurrence proximate to the surgical site suggested surgical seeding. This case demonstrates an unusual site of recurrence of anaplastic ependymoma and highlights a previously underappreciated surgical complication...
- Deciphering HIC1 control pathways to reveal new avenues in cancer therapeuticsBrian R Rood
Center for Cancer and Blood Disorders, Children s National Medical Center, Division of Oncology, 111 Michigan Ave NW, Washington, DC 20010, USA
Expert Opin Ther Targets 17:811-27. 2013..An understanding of this program through identification of HIC1's target genes and their involvement in feedback loops and cell process regulation will yield the ability to leverage this knowledge for therapeutic translation...
- Creation of a PDGF-C Autocrine Loop by HIC1 InactivationBrian Rood; Fiscal Year: 2007..This project seeks to investigate the biologic role of one of these potential therapeutic targets, the PDGF signaling pathway. ..